# No-Live / Read-Only Closure

RUN_ID `20260430T055712Z` processed the remaining automation-owned no-live/read-only gaps after RWO-08B Fullflow completion.

## Result

The repo-local no-live/read-only wrappers are now revalidated or minimized to explicit non-repo blockers:

| Area | Result | Remaining blocker |
|---|---|---|
| `subjectivesv2` | no-live dry-run passed | prior live HTTP 502 still needs changed live/runtime precondition |
| `diseasev3` | no-live dry-run passed | prior live HTTP 400 still needs changed business/Trial precondition |
| `acceptmodv2` RN02/RN03/RN04 | no-live dry-runs passed | future mutation requires fresh server-derived target packet |
| `baseChargeOrder/110` | read-only checked dates 20260425-20260430 | target/date is not first-visit compatible |
| `injectionOrder/310` | read-only master validity validated | no master-validity no-live blocker remains |
| `surgeryOrder/500` | read-only row proof not validated | needs changed source-backed row identity or stop decision |
| `instractionChargeOrder/130` | read-only probes completed | several business/Trial contexts remain unproven |

## Verification

- `npm --prefix web-client test -- --run scripts/__tests__/phase4SoapDiseaseSafeEvidence.test.ts scripts/__tests__/phase4Acceptmodv2OperationEvidence.test.ts scripts/__tests__/phase4BaseChargeFirstVisitEvidence.test.ts scripts/__tests__/phase4MasterValidityEvidence.test.ts scripts/__tests__/phase4InstructionChargePreconditionsEvidence.test.ts scripts/__tests__/phase4Medicalmodv2SafeEvidence.test.ts`: PASS, 86 tests.
- Wrapper dry-runs: PASS for `subjectivesv2`, `diseasev3`, `acceptmodv2` RN02/RN03/RN04, base-charge, injection, surgery, instruction-charge.
- Read-only wrappers: executed for base-charge, injection, surgery, and instruction-charge.

## Safety

- Live Trial mutation: false
- Production ORCA: false
- S3/object storage: false
- Credentials printed/captured: false
- Diagnostic artifacts captured: false
- Raw artifacts committed/packaged: false

## Claim Boundary

This is no-live/read-only closure only. It does not claim Trial mutation success, broad clinical coverage, production ORCA readiness, S3/object-storage readiness, rollback rehearsal, owner final GO/NO-GO, or final release readiness.
